Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?
Authors:
Journal: Journal of the American Heart Association
Publication Type: Journal Article
Date: 2020
DOI: PMC7033879
ID: 32013699
Chemical List
- Reactive Oxygen Species
Reference List
- Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149.|||Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978–985.|||Kloner RA, Ellis SG, Carlson NV, Braunwald E. Coronary reperfusion for the treatment of acute myocardial infarction: postischemic ventricular dysfunction. Cardiology. 1983;70:233–246.|||DeBoer LW, Ingwall JS, Kloner RA, Braunwald E. Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci USA. 1980;77:5471–5475.|||Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987;76:906–915.|||Charlat ML, O'Neill PG, Hartley CJ, Roberts R, Bolli R. Prolonged abnormalities of left ventricular diastolic wall thinning in the “stunned” myocardium in conscious dogs: time course and relation to systolic function. J Am Coll Cardiol. 1989;13:185–194.|||Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol. 1983;1:1047–1055.|||Arnold JM, Braunwald E, Sandor T, Kloner RA. Inotropic stimulation of reperfused myocardium with dopamine: effects on infarct size and myocardial function. J Am Coll Cardiol. 1985;6:1026–1034.|||Ellis SG, Wynne J, Braunwald E, Henschke CI, Sandor T, Kloner RA. Response of reperfusion‐salvaged, stunned myocardium to inotropic stimulation. Am Heart J. 1984;107:13–19.|||Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609–634.|||Kloner RA, Przyklenk K, Patel B. Altered myocardial states. The stunned and hibernating myocardium. Am J Med. 1989;86:14–22.|||Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA. 1987;84:1404–1407.|||Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the “stunned myocardium”. Circ Res. 1986;58:148–156.|||Przyklenk K, Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium. J Am Coll Cardiol. 1989;13:1176–1183.|||Przyklenk K, Kloner RA. Effect of verapamil on postischemic “stunned” myocardium: importance of the timing of treatment. J Am Coll Cardiol. 1988;11:614–623.|||Guaricci AI, Bulzis G, Pontone G, Scicchitano P, Carbonara R, Rabbat M, De Santis D, Ciccone MM. Current interpretation of myocardial stunning. Trends Cardiovasc Med. 2018;28:263–271.|||Hale SL, Kloner RA. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006;11:249–255.|||Kloner RA, Allen J, Cox TA, Zheng Y, Ruiz CE. Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol. 1991;68:329–334.|||Kloner RA, Przyklenk K. Stunned and hibernating myocardium. Annu Rev Med. 1991;42:1–8.|||Patel B, Kloner RA, Przyklenk K, Braunwald E. Postischemic myocardial “stunning”: a clinically relevant phenomenon. Ann Intern Med. 1988;108:626–628.|||Touchstone DA, Beller GA, Nygaard TW, Tedesco C, Kaul S. Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two‐dimensional echocardiography. J Am Coll Cardiol. 1989;13:1506–1513.|||Wdowiak‐Okrojek K, Wejner‐Mik P, Kasprzak JD, Lipiec P. Recovery of regional systolic and diastolic myocardial function after acute myocardial infarction evaluated by two‐dimensional speckle tracking echocardiography. Clin Physiol Funct Imaging. 2019;39:177–181.|||Calabretta R, Castello A, Linguanti F, Tutino F, Ciaccio A, Giglioli C, Sciagra R. Prediction of functional recovery after primary PCI using the estimate of myocardial salvage in gated SPECT early after acute myocardial infarction. Eur J Nucl Med Mol Imaging. 2018;45:530–537.|||Sharif D, Matanis W, Sharif‐Rasslan A, Rosenschein U. Doppler echocardiographic myocardial stunning index predicts recovery of left ventricular systolic function after primary percutaneous coronary intervention. Echocardiography. 2016;33:1465–1471.|||McCormick LM, Hoole SP, White PA, Read PA, Axell RG, Clarke SJ, O'Sullivan M, West NE, Dutka DP. Pre‐treatment with glucagon‐like Peptide‐1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv. 2015;8:292–301.|||Maranta F, Tondi L, Agricola E, Margonato A, Rimoldi O, Camici PG. Ivabradine reduces myocardial stunning in patients with exercise‐inducible ischaemia. Basic Res Cardiol. 2015;110:55.|||Richard C. Stress‐related cardiomyopathies. Ann Intensive Care. 2011;1:39.|||Chen W, Dilsizian V. Exploring the pathophysiology of takotsubo cardiomyopathy. Curr Cardiol Rep. 2017;19:53.|||Ranieri M, Finsterer J, Bedini G, Parati EA, Bersano A. Takotsubo syndrome: clinical features, pathogenesis, treatment, and relationship with cerebrovascular diseases. Curr Neurol Neurosci Rep. 2018;18:20.|||Said SM, Saygili E, Rana OR, Genz C, Hahn J, Bali R, Varshney S, Albouaini K, Prondzinsky R, Braun‐Dullaeus RC. Takotsubo cardiomyopathy: what we have learned in the last 25 years? (a comparative literature review). Curr Cardiol Rev. 2016;12:297–303.|||Kloner RA. Lessons learned about stress and the heart after major earthquakes. Am Heart J. 2019;215:20–26.|||Sachdeva J, Dai W, Kloner RA. Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy. J Am Heart Assoc. 2014;3:e000921 DOI: 10.1161/JAHA.114.000921|||Medina de Chazal H, Del Buono MG, Keyser‐Marcus L, Ma L, Moeller FG, Berrocal D, Abbate A. Stress cardiomyopathy diagnosis and treatment: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2018;72:1955–1971.|||Akutsu Y, Kaneko K, Kodama Y, Li HL, Suyama J, Toshida T, Kayano H, Shinozuka A, Gokan T, Kobayashi Y. Reversible T‐wave inversions and neurogenic myocardial stunning in a patient with recurrent stress‐induced cardiomyopathy. Ann Noninvasive Electrocardiol. 2014;19:285–288.|||Murthy SB, Shah S, Rao CP, Bershad EM, Suarez JI. Neurogenic stunned myocardium following acute subarachnoid hemorrhage: pathophysiology and practical considerations. J Intensive Care Med. 2015;30:318–325.|||Biso S, Wongrakpanich S, Agrawal A, Yadlapati S, Kishlyansky M, Figueredo V. A review of neurogenic stunned myocardium. Cardiovasc Psychiatry Neurol. 2017;2017:5842182.|||Mahmoud H, Forni LG, McIntyre CW, Selby NM. Myocardial stunning occurs during intermittent haemodialysis for acute kidney injury. Intensive Care Med. 2017;43:942–944.|||Penny JD, Salerno FR, Brar R, Garcia E, Rossum K, McIntyre CW, Bohm CJ. Intradialytic exercise preconditioning: an exploratory study on the effect on myocardial stunning. Nephrol Dial Transplant. 2019;34:1917–1923.|||Wu AH. Release of cardiac troponin from healthy and damaged myocardium. Front Lab Med. 2017;1:144–150.|||Jaffe AS, Wu AH. Troponin release–reversible or irreversible injury? Should we care? Clin Chem. 2012;58:148–150.|||Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, Keeley EC, Cigarroa JE, Lange RA, Hillis LD, de Lemos JA. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol. 2011;57:2398–2405.|||Weil BR, Young RF, Shen X, Suzuki G, Qu J, Malhotra S, Canty JM Jr. Brief myocardial ischemia produces cardiac troponin I release and focal myocyte apoptosis in the absence of pathological infarction in swine. JACC Basic Transl Sci. 2017;2:105–114.|||Gerber BL, Wijns W, Vanoverschelde JL, Heyndrickx GR, De Bruyne B, Bartunek J, Melin JA. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans. J Am Coll Cardiol. 1999;34:1939–1946.|||Bestetti A, Cuko B, Decarli A, Galli A, Lombardi F. Additional value of systolic wall thickening in myocardial stunning evaluated by stress‐rest gated perfusion SPECT. J Nucl Cardiol. 2019;26:833–840.|||Bestetti A, Cuko B, Gasparini M, De Servi S. Better characterization of dipyridamole‐induced myocardial stunning by systolic wall thickening. A gated perfusion SPECT study. J Nucl Cardiol. 2018. Available at: 10.1007/s12350-018-1340-6.|||Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJ. Post‐extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J. 1978;95:204–209.|||Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211–221.|||Ryan MJ, Perera D. Identifying and managing hibernating myocardium: what's new and what remains unknown? Curr Heart Fail Rep. 2018;15:214–223.|||Rahimtoola SH. Coronary bypass surgery for chronic angina—1981. A perspective. Circulation. 1982;65:225–241.|||Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium”. J Am Coll Cardiol. 1986;8:1467–1470.|||Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G, Sadoshima J, Vatner DE, Vatner SF. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. Circ Res. 2003;92:1233–1239.|||Depre C, Vatner SF. Mechanisms of cell survival in myocardial hibernation. Trends Cardiovasc Med. 2005;15:101–110.|||Canty JM, Fallavollita JA. Chronic hibernation and chronic stunning: a continuum. J Nucl Cardiol. 2000;7:509–527.|||Canty JM, Fallavollita JA. Lessons from experimental models of hibernating myocardium. Coron Artery Dis. 2001;374–380.|||Nihoyannopoulos P, Vanoverschelde JL. Myocardial ischaemia and viability: the pivitol role of echocardiography. Eur Heart J. 2011;32:810–819.|||Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis‐induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009;4:1925–1931.|||Marzullo P, Parodi O, Sambuceti G, Giorgetti A, Picano E, Gimelli A, Salvadori P, L'Abbate A. Residual coronary reserve identifies segmental viability in patients with wall motion abnormalities. J Am Coll Cardiol. 1995;26:342–350.|||Rinaldi CA, Masani ND, Linka AZ, Hall RJ. Effect of repetitive episodes of exercise induced myocardial ischaemia on left ventricular function in patients with chronic stable angina: evidence for cumulative stunning or ischaemic preconditioning? Heart. 1999;81:404–411.|||Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, Bol A, Melin JA. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral‐dependent myocardium. Circulation. 1993;87:1513–1523.|||Verheyen F, Racz R, Borgers M, Driesen RB, Lenders MH, Flameng WJ. Chronic hibernating myocardium in sheep can occur without degenerating events and is reversed after revascularization. Cardiovasc Pathol. 2014;23:160–168.|||Fedele FA, Gewirtz H, Capone RJ, Sharaf B, Most AS. Metabolic response to prolonged reduction of myocardial blood flow distal to a severe coronary artery stenosis. Circulation. 1988;78:729–735.|||Borgers M. Hibernating myocardium: programmed cell survival or programmed cell death? Exp Clin Cardiol. 2002;7:69–72.|||Borgers M, Thone F, Ausma J, Shevalkar B, Flameng WJ. Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis: chronic hibernation? Cardiovasc Pathol. 1993;2:237–245.|||Page BJ, Banas MD, Suzuki G, Weil BR, Young RF, Fallavollita JA, Palka BA, Canty JM Jr. Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia. J Am Coll Cardiol. 2015;65:684–697.|||Lionetti V, Matteucci M, Ribezzo M, Di Silvestre D, Brambilla F, Agostini S, Mauri P, Padeletti L, Pingitore A, Delsedime L, Rinaldi M, Recchia FA, Pucci A. Regional mapping of myocardial hibernation phenotype in idiopathic end‐stage dilated cardiomyopathy. J Cell Mol Med. 2014;18:396–414.|||Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med. 2008;5(suppl 2):S42–S48.|||Gunning MG, Kaprielian RR, Pepper J, Pennell DJ, Sheppard MN, Severs NJ, Fox KM, Underwood SR. The histology of viable and hibernating myocardium in relation to imaging characteristics. J Am Coll Cardiol. 2002;39:428–435.|||Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta‐analysis. J Am Coll Cardiol. 2002;39:1151–1158.|||D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, Ruddy TD, DaSilva J, Humen D, Gulenchyn KY, Freeman M, Racine N, Benard F, Hendry P, Beanlands RS. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR‐2 trial. JACC Cardiovasc Imaging. 2009;2:1060–1068.|||Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne‐Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–1625.|||Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary‐artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–1616.|||Velazquez EJ, Lee KL, Jones RH, Al‐Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne‐Nickens P, Sopko G, Rouleau JL. Coronary‐artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511–1520.|||Athanasuleas C, Buckberg G, Conte J. The STICH trial data: keep it simple. J Thorac Cardiovasc Surg. 2015;149:1682–1683.|||Cortigiani L, Bigi R, Sicari R. Is viability still viable after the STICH trial? Eur Heart J Cardiovasc Imaging. 2012;13:219–226.|||Daggubati R, Arumugham P, Ferguson TB Jr. The world post STICH: is this a “game changer?” A surgeon's perspective–revascularization is still the treatment of choice. Prog Cardiovasc Dis. 2013;55:470–475.|||Gramze NL, Shah DJ. Is there a need to assess myocardial viability in patients presenting with heart failure? Curr Opin Cardiol. 2016;31:501–509.|||Shah BN, Khattar RS, Senior R. The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post‐STICH era. Eur Heart J. 2013;34:1323–1336.|||Srichai MB, Jaber WA. Viability by MRI or PET would have changed the results of the STICH trial. Prog Cardiovasc Dis. 2013;55:487–493.|||Panza JA, Ellis AM, Al‐Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial viability and long‐term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–748.|||Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM. F‐18‐fluorodeoxyglucose positron emission tomography imaging‐assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR‐2). J Am Coll Cardiol. 2007;50:2002–2012.|||Arora Y, Singh RS, Sampath S, Sood A, Singh P, Singh H, Mishra AK, Parmar M. Impact of hibernating and viable myocardium on improvement in perfusion and left ventricular ejection fraction after coronary artery bypass graft. Nucl Med Commun. 2019;40:325–332.|||Glaveckaite S, Valeviciene N, Palionis D, Puronaite R, Serpytis P, Laucevicius A. Prediction of long‐term segmental and global functional recovery of hibernating myocardium after revascularisation based on low dose dobutamine and late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:83.|||Giordano C, Kuraitis D, Beanlands RS, Suuronen EJ, Ruel M. Cell‐based vasculogenic studies in preclinical models of chronic myocardial ischaemia and hibernation. Exp Opin Biol Ther. 2013;13:411–428.|||Weil BR, Suzuki G, Leiker MM, Fallavollita JA, Canty JM Jr. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere‐derived cells in swine with hibernating myocardium. Circ Res. 2015;117:634–644.